勘误：索拉非尼、多西他赛（泰索帝）和顺铂挽救性治疗后维持长春瑞滨用于不可切除/转移性非小细胞肺癌的安全性和有效性评估：西蒙两阶段临床试验的第1阶段：勘误。
Erratum: Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxane) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial: Erratum.
出版信息
Medicine (Baltimore). 2016 Mar 3;95(8):e9727. doi: 10.1097/01.md.0000481355.09097.27. eCollection 2016 Feb.
Abstract
[This corrects the article on p. e2303 in vol. 94, PMID: 26717366.].
摘要
[这更正了第94卷第e2303页上的文章，PMID: 26717366。]
相似文献
1
Erratum: Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxane) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial: Erratum.勘误：索拉非尼、多西他赛（泰索帝）和顺铂挽救性治疗后维持长春瑞滨用于不可切除/转移性非小细胞肺癌的安全性和有效性评估：西蒙两阶段临床试验的第1阶段：勘误。
Medicine (Baltimore). 2016 Mar 3;95(8):e9727. doi: 10.1097/01.md.0000481355.09097.27. eCollection 2016 Feb.
2
ERRATUM.勘误
Int J Bioprint. 2020 Sep 17;6(4):309. doi: 10.18063/ijb.v6i4.309. eCollection 2020.
3
Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.
Cancer. 2000 Mar 1;88(5):1045-50. doi: 10.1002/(sici)1097-0142(20000301)88:5<1045::aid-cncr14>3.0.co;2-j.
4
A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer.
Eur J Cancer. 2000 Jun;36(9):1107-12. doi: 10.1016/s0959-8049(00)00097-6.
5
Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.长春瑞滨和顺铂用于转移性乳腺癌：一种在多西他赛和蒽环类药物治疗后进展患者的挽救方案。
Cancer Invest. 2003;21(4):497-504. doi: 10.1081/cnv-120022358.
6
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.IV期非小细胞肺癌的序贯两线治疗策略：多西他赛-顺铂对比长春瑞滨-顺铂，疾病进展时交叉至单药多西他赛或长春瑞滨：一项随机II期研究的最终结果
Ann Oncol. 2005 Jan;16(1):81-9. doi: 10.1093/annonc/mdi013.
7
Erratum: Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait.勘误：科威特非小细胞肺癌患者的表皮生长因子受体突变
J Cytol. 2016 Apr-Jun;33(2):113. doi: 10.4103/0970-9371.182541.
8
A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC).顺铂和长春瑞滨（PVn）用于晚期乳腺癌（ABC）的临床II期研究。
Am J Clin Oncol. 2005 Aug;28(4):393-8. doi: 10.1097/01.coc.0000145335.39398.ee.
9
Erratum: From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer [Erratum].勘误：从3D球体到荷瘤小鼠：曲妥珠单抗-多西他赛免疫脂质体在乳腺癌中的疗效与分布研究[勘误]
Int J Nanomedicine. 2018 Dec 31;14:335. doi: 10.2147/IJN.S197654. eCollection 2019.
10
Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.多西他赛序贯长春瑞滨和顺铂用于特定ⅢB期和Ⅳ期非小细胞肺癌的初步研究
Lung Cancer. 2001 Nov;34(2):271-7. doi: 10.1016/s0169-5002(01)00251-3.
本文引用的文献
1
Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].舒尼替尼、多西他赛（泰索帝）和顺铂挽救治疗后维持使用长春瑞滨用于不可切除/转移性非小细胞肺癌的安全性和疗效评估：Simon两阶段临床试验的第1阶段。[已校正]
Medicine (Baltimore). 2015 Dec;94(52):e2303. doi: 10.1097/MD.0000000000002303.
Zotero 插件